Becton Dickinson and Company (BDX) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-02, Becton Dickinson and Company (NYSE: BDX) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $197.88 (-0.23% 1D, market cap $54.03B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BDX ranks #105 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), BDX carries a Roarable C+ (67/100 RQD), trailing P/E of 32.2x, gross margin of 45.4%, and ROIC of 4.9%. By comparison, BSX (Boston Scientific Corporation) holds a C grade (62/100 RQD, P/E 22.0x, ROIC 9.2%, cap $61.87B) and MDLN (Medline Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC 8.2%, cap $42.07B). Among the 5-stock peer group, BSX leads on earnings multiple (22.0x) while MMM leads on capital efficiency (32.9% ROIC).
Per BDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000010795), Becton Dickinson and Company generated $21.84B in revenue (+8.2% YoY), $1.68B in net income, and $0 in free cash flow against $54.84B in total assets and $16.92B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±4.2% realized swing band)
Altman Z-Score 2.22 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 8/9
Capital intensity & 11.8% operating margin leave 10 pts on the table
Even with a 67/100 (C+) score, BDX faces multiple-compression risk if 32.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 42.9% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($186.88) or 200D SMA ($166.33) invalidates the momentum regime and cuts Target Base ($205.89) toward Bear Floor ($160.59).
Becton Dickinson and Company (BDX) slipped -0.23% to $197.88, trading at 96% of its 52-week range ($127.59 – $200.47). Solid 45% profit margin (5% return on capital), mixed timing at 32x P/E—hold if owned, no rush to chase.
Yahoo Finance report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
BDX launches its Liverty TIPS Stent Graft in the United States, offering greater precision and flexibility in portal hypertension treatment.
Optimize ROI with segment, regional, competitive and tariff insights that sharpen sourcing, market positioning and revenue strategies.Dublin, Nov. 02, 2026 (GLOBE NEWSWIRE) -- "Flow Cytometry Products and Services - Glob
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BDX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BDX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Becton Dickinson and Company (BDX) ranks #105 by composite RQD confidence (67/100, grade C+) and #37 by equity capitalization ($54.03B). Within this direct 5-issuer industry benchmark cohort, BSX leads on earnings valuation at 22.0x trailing P/E, while MMM leads on capital efficiency and profitability with 32.9% ROIC and 39.9% gross margin. RMD currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with BDX at 67/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BDX
ACTIVE
Becton Dickinson and Company | C+ | 67/100 | 32.2x | 45.4% | 4.9% | -0.23% | $54.03B | Benchmark Subject |
| BSX Boston Scientific Corporation | C | 62/100 | 22.0x | 69.0% | 9.2% | -1.66% | $61.87B | /bsx-vs-bdx → |
| MDLN Medline Inc. | D | 44/100 | — | — | 8.2% | +0.38% | $42.07B | /mdln-vs-bdx → |
| RMD ResMed Inc. | A | 86/100 | 25.4x | 59.4% | 22.9% | -9.05% | $35.56B | /rmd-vs-bdx → |
| MMM 3M Company | C | 65/100 | 28.2x | 39.9% | 32.9% | -1.70% | $91.65B | /mmm-vs-bdx → |
In its most recent audited fiscal period (FY2025, filed 2025-09-30), Becton Dickinson and Company (BDX) reported GAAP revenue of $21.84B (+8.2% vs. FY2024 revenue of $20.18B , and +12.7% cumulative change since FY2023) , GAAP net income of $1.68B, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, BDX closed FY2025 with $54.84B in total assets against $16.92B in total debt (Altman Z-Score: 2.22, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $21.84B | $1.68B | — | — | $54.84B | $16.92B |
| FY2024 (FY) | 2024-09-30 | $20.18B | $1.71B | — | — | $54.66B | $17.44B |
| FY2023 (FY) | 2023-09-30 | $19.37B | $1.48B | — | — | $29.71B | $6.95B |
As of 2026-11-02, Becton Dickinson and Company (NYSE: BDX) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $197.88 (-0.23% 1D, market cap $54.03B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BDX ranks #105 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), BDX carries a Roarable C+ (67/100 RQD), trailing P/E of 32.2x, gross margin of 45.4%, and ROIC of 4.9%. By comparison, BSX (Boston Scientific Corporation) holds a C grade (62/100 RQD, P/E 22.0x, ROIC 9.2%, cap $61.87B) and MDLN (Medline Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC 8.2%, cap $42.07B). Among the 5-stock peer group, BSX leads on earnings multiple (22.0x) while MMM leads on capital efficiency (32.9% ROIC).
Per BDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000010795), Becton Dickinson and Company generated $21.84B in revenue (+8.2% YoY), $1.68B in net income, and $0 in free cash flow against $54.84B in total assets and $16.92B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
BDX last traded at $197.88 (-0.23% on volume of 2,920,047 shares), positioning the stock +5.89% above its 50-day simple moving average ($186.88) and +18.97% above its 200-day simple moving average ($166.33). Across its 52-week range of $127.59 to $200.47, BDX sits at the 96.4% percentile with a 14-day RSI of 64.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.2% ($189.57 to $206.19).
Why BDX Stock slipped -0.23% Today — RQD Quant Desk Flash. Solid 45% profit margin (5% return on capital), mixed timing at 32x P/E—hold if owned, no rush to chase.
Per the Roarable RQD rating, BDX scores 67 out of 100 (letter grade C+; verdict: Roarable Hold — Upper Neutral / Watch for Breakout). The five pillars are:
Taken together, the rating points to a stock whose institutional support and balance sheet strength are offset by thin cash returns and a premium valuation. The verdict's "Watch for Breakout" language implies that the rating is awaiting a catalyst for re-rating, rather than signaling an immediate directional call. The price of 198.34 sits near the top of the 52-week range of $127.59 to $200.47 (per market data), so upside from current levels depends on continued execution and sentiment improvement. This is an analytical framing, not personalized advice.
Becton Dickinson and Company is a NYSE-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry (per the company profile). The source data does not describe its specific product lines, customer base, or revenue model. Per the SEC financials, the company reported FY 2025 revenue of $21840.0M, indicating a large-scale operation. Gross margin is 45.4% per market data.
The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals (supply_chain: NONE), so no butterfly-derived catalysts are available.
Real-time company headlines, analyst actions, and sector developments for Becton Dickinson and Company (BDX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Becton Dickinson and Company (BDX) market action, institutional positioning, and fundamental catalysts.
Welcome to the BDX (Becton Dickinson and Company) Roar Pit. Current RQD Composite is 67/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.2x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on BDX, but look at what you are paying: 32.2x trailing P/E with 45.4% gross margins. Unless Becton Dickinson and Company expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on BDX, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $198.34 (52-wk range $127.59 - $200.47), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).